NUVATION BIO announced Tuesday that the FDA has accepted its new drug application for its lead immune-oncology asset, a critical step that catalyzes the upcoming Phase 3 review and significantly de-risks the company's near-term clinical development timeline. The acceptance validates the asset’s pathway and signals to the market that Nuvation expects to remain competitive in the lucrative immuno-oncology landscape through the anticipated pivotal enrollment.